Home World News Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of... World News Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma By Ogkologos - April 27, 2026 294 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib February 1, 2021 Approximately 1 Million of New Maternal Orphans Due to Cancer in... November 28, 2022 Open Enrollment for 2022 Affordable Care Act Plans is Here! November 1, 2021 Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for... February 4, 2025 Load more HOT NEWS Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... Diving into our role in 50 top cancer drugs Stopping neuropathy: One of chemotherapy’s most challenging side effects New Imaging Tool Could Predict Whether Hormone Therapy Will Work in...
